rabbit polyclonal anti mapk8 9 Search Results


95
Santa Cruz Biotechnology anti mitogen activated protein kinase mapk 8 9
FIG. 7. Activation of the extracellular-signal regulated kinases MAPK1/3 (ERK2/1) is not involved in Tyr14 phosphorylation of caveolin 1 (CAV1) by H2O2 in fetoplacental artery endothelial cells (oFPAEC). Serum- starved oFPAEC were pretreated with or without increasing concentrations of the specific mitogen-activated protein kinase 1 (termed MEK1) inhibitor PD98059 for 60 min, followed by treatment with or without 0.2 mM H2O2 for 20 min. Total cell extracts were prepared and cellular proteins (20 mg/ lane) were analyzed for phosphorylation of MAPK1/3 (a, upper panel) by Western blotting with a <t>phospho-MAPK</t> antibody (1:1000) recognizing activated MAPK1/3 or by Western blotting a specific anti-CAV1 polyclonal antibody (pCAV1 pAb, 1:1000) as described in Figure 2 (b, upper panel). Total MAPK1/3 and CAV1 levels were measured by Western blotting with an anti-panMAPK1/3 antibody (1:2000) and an anti-CAV1 antibody (CAV1 pAb, 1:40 000) for monitoring sample loading (lower panels). Represen- tative blots of phospho-MAPK1/3, Tyr14 phosphorylated CAV1, and total MAPK1/3 and CAV1 of atypical experiment are shown. Data of mean 6 SEM (n 5 3) of phospho-MAPK1/3 and Tyr14 phosphorylated CAV1 are summarized in their corresponding graphs. * P , 0.05 differ significantly from controls.
Anti Mitogen Activated Protein Kinase Mapk 8 9, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti+mapk8+9/pm15958730-65-2-33?v=Santa+Cruz+Biotechnology
Average 95 stars, based on 1 article reviews
anti mitogen activated protein kinase mapk 8 9 - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier

93
Boster Bio circ mapk9 probe
FIG. 7. Activation of the extracellular-signal regulated kinases MAPK1/3 (ERK2/1) is not involved in Tyr14 phosphorylation of caveolin 1 (CAV1) by H2O2 in fetoplacental artery endothelial cells (oFPAEC). Serum- starved oFPAEC were pretreated with or without increasing concentrations of the specific mitogen-activated protein kinase 1 (termed MEK1) inhibitor PD98059 for 60 min, followed by treatment with or without 0.2 mM H2O2 for 20 min. Total cell extracts were prepared and cellular proteins (20 mg/ lane) were analyzed for phosphorylation of MAPK1/3 (a, upper panel) by Western blotting with a <t>phospho-MAPK</t> antibody (1:1000) recognizing activated MAPK1/3 or by Western blotting a specific anti-CAV1 polyclonal antibody (pCAV1 pAb, 1:1000) as described in Figure 2 (b, upper panel). Total MAPK1/3 and CAV1 levels were measured by Western blotting with an anti-panMAPK1/3 antibody (1:2000) and an anti-CAV1 antibody (CAV1 pAb, 1:40 000) for monitoring sample loading (lower panels). Represen- tative blots of phospho-MAPK1/3, Tyr14 phosphorylated CAV1, and total MAPK1/3 and CAV1 of atypical experiment are shown. Data of mean 6 SEM (n 5 3) of phospho-MAPK1/3 and Tyr14 phosphorylated CAV1 are summarized in their corresponding graphs. * P , 0.05 differ significantly from controls.
Circ Mapk9 Probe, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti+mapk8+9/pmc10759731-55-4-10?v=Boster+Bio
Average 93 stars, based on 1 article reviews
circ mapk9 probe - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

94
Proteintech anti jnk
FIG. 7. Activation of the extracellular-signal regulated kinases MAPK1/3 (ERK2/1) is not involved in Tyr14 phosphorylation of caveolin 1 (CAV1) by H2O2 in fetoplacental artery endothelial cells (oFPAEC). Serum- starved oFPAEC were pretreated with or without increasing concentrations of the specific mitogen-activated protein kinase 1 (termed MEK1) inhibitor PD98059 for 60 min, followed by treatment with or without 0.2 mM H2O2 for 20 min. Total cell extracts were prepared and cellular proteins (20 mg/ lane) were analyzed for phosphorylation of MAPK1/3 (a, upper panel) by Western blotting with a <t>phospho-MAPK</t> antibody (1:1000) recognizing activated MAPK1/3 or by Western blotting a specific anti-CAV1 polyclonal antibody (pCAV1 pAb, 1:1000) as described in Figure 2 (b, upper panel). Total MAPK1/3 and CAV1 levels were measured by Western blotting with an anti-panMAPK1/3 antibody (1:2000) and an anti-CAV1 antibody (CAV1 pAb, 1:40 000) for monitoring sample loading (lower panels). Represen- tative blots of phospho-MAPK1/3, Tyr14 phosphorylated CAV1, and total MAPK1/3 and CAV1 of atypical experiment are shown. Data of mean 6 SEM (n 5 3) of phospho-MAPK1/3 and Tyr14 phosphorylated CAV1 are summarized in their corresponding graphs. * P , 0.05 differ significantly from controls.
Anti Jnk, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti+mapk8+9/pmc11913804-87-35-36?v=Proteintech
Average 94 stars, based on 1 article reviews
anti jnk - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

96
Proteintech tlr4 proteintech
Expression and activity of <t>TLR4</t> and TLR9 in human primary intestinal epithelial cells. a Western blot analysis of TLR4 and TLR9 in P-IECs, 0 h (basal) and 24 h after stimulation with TLR4 (LPS) or TLR9 agonist (ODN2006). GAPDH was used as reference protein. b Quantitative RT-PCR showing the levels of TLR4 and TLR9 in P-IECs 0 h, 2 h, and 6 h after stimulation with TLR4 (LPS) or TLR9 agonist (ODN2006). GAPDH was used as reference gene. n = 7/group. c, d HEK-Dual cells were stimulated with TLR9 agonist (ODN2006) for 2 h, 6 h, 11 h, and 24 h and the ( c ) optical density (OD 630 ) or ( d ) relative light units (RLUs) were compared with non-treated cells (basal). n = 4/group. e, f HEK-Dual cells were treated with a TLR9 agonist (A, ODN2006) or with inhibitor (INH-18) and agonist (I + A) in two different concentrations, 0.1 µg/ml ( e ) and 1.0 µg/ml ( f ), and were compared to non-treated cells. Luminescence signal was measured with a TECAN luminescence reader. n = 4/group. g MTT assay showing cell viability in different dilutions of the control formula, compared to control (Co) cells incubated with medium. n = 8/group. Data were analyzed by two-way ANOVA ( b–d ) or one-way ANOVA ( g ) followed by Newman-Keuls post hoc test or Student’s t -test ( e, f ) and are represented as mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001
Tlr4 Proteintech, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti+mapk8+9/pmc11579199-76-55-56?v=Proteintech
Average 96 stars, based on 1 article reviews
tlr4 proteintech - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

96
Proteintech mapk14
Expression and activity of <t>TLR4</t> and TLR9 in human primary intestinal epithelial cells. a Western blot analysis of TLR4 and TLR9 in P-IECs, 0 h (basal) and 24 h after stimulation with TLR4 (LPS) or TLR9 agonist (ODN2006). GAPDH was used as reference protein. b Quantitative RT-PCR showing the levels of TLR4 and TLR9 in P-IECs 0 h, 2 h, and 6 h after stimulation with TLR4 (LPS) or TLR9 agonist (ODN2006). GAPDH was used as reference gene. n = 7/group. c, d HEK-Dual cells were stimulated with TLR9 agonist (ODN2006) for 2 h, 6 h, 11 h, and 24 h and the ( c ) optical density (OD 630 ) or ( d ) relative light units (RLUs) were compared with non-treated cells (basal). n = 4/group. e, f HEK-Dual cells were treated with a TLR9 agonist (A, ODN2006) or with inhibitor (INH-18) and agonist (I + A) in two different concentrations, 0.1 µg/ml ( e ) and 1.0 µg/ml ( f ), and were compared to non-treated cells. Luminescence signal was measured with a TECAN luminescence reader. n = 4/group. g MTT assay showing cell viability in different dilutions of the control formula, compared to control (Co) cells incubated with medium. n = 8/group. Data were analyzed by two-way ANOVA ( b–d ) or one-way ANOVA ( g ) followed by Newman-Keuls post hoc test or Student’s t -test ( e, f ) and are represented as mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001
Mapk14, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti+mapk8+9/pmc04918526-47-16-17?v=Proteintech
Average 96 stars, based on 1 article reviews
mapk14 - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

96
Santa Cruz Biotechnology anti phosphotyrosine py99 monoclonal antibody mab
FIG. 1. Temporal protein tyrosine phosphorylation in response to H2O2 exposure in fetoplacental artery endothelial cells (oFPAEC)—immunolog- ical identification of tyrosine phosphorylated caveolin 1 (CAV1). a) Serum- starved oFPAEC were treated with 0.2 mM H2O2 for up to 120 min. Total- cell extracts were prepared and cellular proteins (20 mg/lane) were sub- jected to 12% SDS-PAGE fractionation and transferred on Immobilon-P membranes. Total tyrosine phosphorylated proteins were detected by Western blotting (WB) with a specific anti-phosphotyrosine <t>monoclonal</t> antibody <t>(PY99</t> mAb, 1:1000). b) The oFPAEC were treated with or with- out 0.5 mM H2O2 for 20 or 60 min, total tyrosine phosphorylated proteins were immunoprecipitated (IP). The IP samples were analyzed by Western blotting with a specific anti-CAV1 polyclonal antibody (CAV1 pAb, 1: 40 000).
Anti Phosphotyrosine Py99 Monoclonal Antibody Mab, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti+mapk8+9/pm15958730-65-26-33?v=Santa+Cruz+Biotechnology
Average 96 stars, based on 1 article reviews
anti phosphotyrosine py99 monoclonal antibody mab - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

92
Boster Bio anti mapk 8 9 10
FIG. 1. Temporal protein tyrosine phosphorylation in response to H2O2 exposure in fetoplacental artery endothelial cells (oFPAEC)—immunolog- ical identification of tyrosine phosphorylated caveolin 1 (CAV1). a) Serum- starved oFPAEC were treated with 0.2 mM H2O2 for up to 120 min. Total- cell extracts were prepared and cellular proteins (20 mg/lane) were sub- jected to 12% SDS-PAGE fractionation and transferred on Immobilon-P membranes. Total tyrosine phosphorylated proteins were detected by Western blotting (WB) with a specific anti-phosphotyrosine <t>monoclonal</t> antibody <t>(PY99</t> mAb, 1:1000). b) The oFPAEC were treated with or with- out 0.5 mM H2O2 for 20 or 60 min, total tyrosine phosphorylated proteins were immunoprecipitated (IP). The IP samples were analyzed by Western blotting with a specific anti-CAV1 polyclonal antibody (CAV1 pAb, 1: 40 000).
Anti Mapk 8 9 10, supplied by Boster Bio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti+mapk8+9/pm37188995-34-53-62?v=Boster+Bio
Average 92 stars, based on 1 article reviews
anti mapk 8 9 10 - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier

Image Search Results


FIG. 7. Activation of the extracellular-signal regulated kinases MAPK1/3 (ERK2/1) is not involved in Tyr14 phosphorylation of caveolin 1 (CAV1) by H2O2 in fetoplacental artery endothelial cells (oFPAEC). Serum- starved oFPAEC were pretreated with or without increasing concentrations of the specific mitogen-activated protein kinase 1 (termed MEK1) inhibitor PD98059 for 60 min, followed by treatment with or without 0.2 mM H2O2 for 20 min. Total cell extracts were prepared and cellular proteins (20 mg/ lane) were analyzed for phosphorylation of MAPK1/3 (a, upper panel) by Western blotting with a phospho-MAPK antibody (1:1000) recognizing activated MAPK1/3 or by Western blotting a specific anti-CAV1 polyclonal antibody (pCAV1 pAb, 1:1000) as described in Figure 2 (b, upper panel). Total MAPK1/3 and CAV1 levels were measured by Western blotting with an anti-panMAPK1/3 antibody (1:2000) and an anti-CAV1 antibody (CAV1 pAb, 1:40 000) for monitoring sample loading (lower panels). Represen- tative blots of phospho-MAPK1/3, Tyr14 phosphorylated CAV1, and total MAPK1/3 and CAV1 of atypical experiment are shown. Data of mean 6 SEM (n 5 3) of phospho-MAPK1/3 and Tyr14 phosphorylated CAV1 are summarized in their corresponding graphs. * P , 0.05 differ significantly from controls.

Journal: Biology of reproduction

Article Title: Tyrosine phosphorylation of caveolin 1 by oxidative stress is reversible and dependent on the c-src tyrosine kinase but not mitogen-activated protein kinase pathways in placental artery endothelial cells.

doi: 10.1095/biolreprod.105.040881

Figure Lengend Snippet: FIG. 7. Activation of the extracellular-signal regulated kinases MAPK1/3 (ERK2/1) is not involved in Tyr14 phosphorylation of caveolin 1 (CAV1) by H2O2 in fetoplacental artery endothelial cells (oFPAEC). Serum- starved oFPAEC were pretreated with or without increasing concentrations of the specific mitogen-activated protein kinase 1 (termed MEK1) inhibitor PD98059 for 60 min, followed by treatment with or without 0.2 mM H2O2 for 20 min. Total cell extracts were prepared and cellular proteins (20 mg/ lane) were analyzed for phosphorylation of MAPK1/3 (a, upper panel) by Western blotting with a phospho-MAPK antibody (1:1000) recognizing activated MAPK1/3 or by Western blotting a specific anti-CAV1 polyclonal antibody (pCAV1 pAb, 1:1000) as described in Figure 2 (b, upper panel). Total MAPK1/3 and CAV1 levels were measured by Western blotting with an anti-panMAPK1/3 antibody (1:2000) and an anti-CAV1 antibody (CAV1 pAb, 1:40 000) for monitoring sample loading (lower panels). Represen- tative blots of phospho-MAPK1/3, Tyr14 phosphorylated CAV1, and total MAPK1/3 and CAV1 of atypical experiment are shown. Data of mean 6 SEM (n 5 3) of phospho-MAPK1/3 and Tyr14 phosphorylated CAV1 are summarized in their corresponding graphs. * P , 0.05 differ significantly from controls.

Article Snippet: Materials Anti-CAV1, anti-mitogen-activated protein kinase (MAPK) 8/9 (also termed Jun-NH2-terminal kinase JNK1/2), anti-MAPK11 (also termed p38mapk), and anti-c-src tyrosine kinase (CSK) rabbit polyclonal antibodies (pAb) and anti-phosphotyrosine (PY99) monoclonal antibody (mAb) were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).

Techniques: Activation Assay, Phospho-proteomics, Western Blot

Expression and activity of TLR4 and TLR9 in human primary intestinal epithelial cells. a Western blot analysis of TLR4 and TLR9 in P-IECs, 0 h (basal) and 24 h after stimulation with TLR4 (LPS) or TLR9 agonist (ODN2006). GAPDH was used as reference protein. b Quantitative RT-PCR showing the levels of TLR4 and TLR9 in P-IECs 0 h, 2 h, and 6 h after stimulation with TLR4 (LPS) or TLR9 agonist (ODN2006). GAPDH was used as reference gene. n = 7/group. c, d HEK-Dual cells were stimulated with TLR9 agonist (ODN2006) for 2 h, 6 h, 11 h, and 24 h and the ( c ) optical density (OD 630 ) or ( d ) relative light units (RLUs) were compared with non-treated cells (basal). n = 4/group. e, f HEK-Dual cells were treated with a TLR9 agonist (A, ODN2006) or with inhibitor (INH-18) and agonist (I + A) in two different concentrations, 0.1 µg/ml ( e ) and 1.0 µg/ml ( f ), and were compared to non-treated cells. Luminescence signal was measured with a TECAN luminescence reader. n = 4/group. g MTT assay showing cell viability in different dilutions of the control formula, compared to control (Co) cells incubated with medium. n = 8/group. Data were analyzed by two-way ANOVA ( b–d ) or one-way ANOVA ( g ) followed by Newman-Keuls post hoc test or Student’s t -test ( e, f ) and are represented as mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001

Journal: European Journal of Nutrition

Article Title: Different infant formulas can activate toll-like receptor 9 in vitro and inhibit interleukin 6 in human primary intestinal epithelial cells

doi: 10.1007/s00394-024-03507-7

Figure Lengend Snippet: Expression and activity of TLR4 and TLR9 in human primary intestinal epithelial cells. a Western blot analysis of TLR4 and TLR9 in P-IECs, 0 h (basal) and 24 h after stimulation with TLR4 (LPS) or TLR9 agonist (ODN2006). GAPDH was used as reference protein. b Quantitative RT-PCR showing the levels of TLR4 and TLR9 in P-IECs 0 h, 2 h, and 6 h after stimulation with TLR4 (LPS) or TLR9 agonist (ODN2006). GAPDH was used as reference gene. n = 7/group. c, d HEK-Dual cells were stimulated with TLR9 agonist (ODN2006) for 2 h, 6 h, 11 h, and 24 h and the ( c ) optical density (OD 630 ) or ( d ) relative light units (RLUs) were compared with non-treated cells (basal). n = 4/group. e, f HEK-Dual cells were treated with a TLR9 agonist (A, ODN2006) or with inhibitor (INH-18) and agonist (I + A) in two different concentrations, 0.1 µg/ml ( e ) and 1.0 µg/ml ( f ), and were compared to non-treated cells. Luminescence signal was measured with a TECAN luminescence reader. n = 4/group. g MTT assay showing cell viability in different dilutions of the control formula, compared to control (Co) cells incubated with medium. n = 8/group. Data were analyzed by two-way ANOVA ( b–d ) or one-way ANOVA ( g ) followed by Newman-Keuls post hoc test or Student’s t -test ( e, f ) and are represented as mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: The following primary antibodies were used: rabbit polyclonal anti-phospho-MAPK1/2 (Thr202/Tyr204; 1:2000; #9101; Cell Signaling, Ipswich, USA), rabbit monoclonal anti-phospho-IKBA (Ser32; 1:2000; #2859; Cell Signaling), rabbit monoclonal anti-phospho-MAPK14 (Thr180/Tyr182; 1:2000; #4511; Cell Signaling), mouse monoclonal anti-phospho-MAPK8/9 (Thr183/Tyr185; 1:2000; #9255; Cell Signaling), rabbit monoclonal anti-phospho-IRAK4 (Thr345/Ser346; 1:2000; #11,927; Cell Signaling), rabbit monoclonal anti-IL6 (1:2000; #12,153; Cell Signaling), TLR4 Proteintech 1:1000, and TLR4 Novus 1:1000.

Techniques: Expressing, Activity Assay, Western Blot, Quantitative RT-PCR, MTT Assay, Control, Incubation

IL6 levels were decreased through various infant formulas in human primary intestinal epithelial cells; in contrast IL6 levels were increased due to TLR9 inhibition. The following phosphorylation stages and proteins were investigated by Western blot analysis in human P-IECs: TLR9, TLR4, pMAPK1/2 and MAPK1/2, pMAPK8/9 and MAPK8/9, pp38 and p38, pIRAK4 and IRAK4, IL6, NFKB, pIKB and IKB. HEK-Dual cells were cultivated in medium, PF, CF, and PHF in a 1/25 dilution, with TLR9 and TLR4 inhibitor (0.1 µg/ml) and non-treated HEK-Dual cells served as reference. In addition, the cells were incubated with L. fermentum CECT5716 (LC) (10 10 CFUs) for 30 min. GAPDH was used as reference protein

Journal: European Journal of Nutrition

Article Title: Different infant formulas can activate toll-like receptor 9 in vitro and inhibit interleukin 6 in human primary intestinal epithelial cells

doi: 10.1007/s00394-024-03507-7

Figure Lengend Snippet: IL6 levels were decreased through various infant formulas in human primary intestinal epithelial cells; in contrast IL6 levels were increased due to TLR9 inhibition. The following phosphorylation stages and proteins were investigated by Western blot analysis in human P-IECs: TLR9, TLR4, pMAPK1/2 and MAPK1/2, pMAPK8/9 and MAPK8/9, pp38 and p38, pIRAK4 and IRAK4, IL6, NFKB, pIKB and IKB. HEK-Dual cells were cultivated in medium, PF, CF, and PHF in a 1/25 dilution, with TLR9 and TLR4 inhibitor (0.1 µg/ml) and non-treated HEK-Dual cells served as reference. In addition, the cells were incubated with L. fermentum CECT5716 (LC) (10 10 CFUs) for 30 min. GAPDH was used as reference protein

Article Snippet: The following primary antibodies were used: rabbit polyclonal anti-phospho-MAPK1/2 (Thr202/Tyr204; 1:2000; #9101; Cell Signaling, Ipswich, USA), rabbit monoclonal anti-phospho-IKBA (Ser32; 1:2000; #2859; Cell Signaling), rabbit monoclonal anti-phospho-MAPK14 (Thr180/Tyr182; 1:2000; #4511; Cell Signaling), mouse monoclonal anti-phospho-MAPK8/9 (Thr183/Tyr185; 1:2000; #9255; Cell Signaling), rabbit monoclonal anti-phospho-IRAK4 (Thr345/Ser346; 1:2000; #11,927; Cell Signaling), rabbit monoclonal anti-IL6 (1:2000; #12,153; Cell Signaling), TLR4 Proteintech 1:1000, and TLR4 Novus 1:1000.

Techniques: Inhibition, Phospho-proteomics, Western Blot, Incubation

FIG. 1. Temporal protein tyrosine phosphorylation in response to H2O2 exposure in fetoplacental artery endothelial cells (oFPAEC)—immunolog- ical identification of tyrosine phosphorylated caveolin 1 (CAV1). a) Serum- starved oFPAEC were treated with 0.2 mM H2O2 for up to 120 min. Total- cell extracts were prepared and cellular proteins (20 mg/lane) were sub- jected to 12% SDS-PAGE fractionation and transferred on Immobilon-P membranes. Total tyrosine phosphorylated proteins were detected by Western blotting (WB) with a specific anti-phosphotyrosine monoclonal antibody (PY99 mAb, 1:1000). b) The oFPAEC were treated with or with- out 0.5 mM H2O2 for 20 or 60 min, total tyrosine phosphorylated proteins were immunoprecipitated (IP). The IP samples were analyzed by Western blotting with a specific anti-CAV1 polyclonal antibody (CAV1 pAb, 1: 40 000).

Journal: Biology of reproduction

Article Title: Tyrosine phosphorylation of caveolin 1 by oxidative stress is reversible and dependent on the c-src tyrosine kinase but not mitogen-activated protein kinase pathways in placental artery endothelial cells.

doi: 10.1095/biolreprod.105.040881

Figure Lengend Snippet: FIG. 1. Temporal protein tyrosine phosphorylation in response to H2O2 exposure in fetoplacental artery endothelial cells (oFPAEC)—immunolog- ical identification of tyrosine phosphorylated caveolin 1 (CAV1). a) Serum- starved oFPAEC were treated with 0.2 mM H2O2 for up to 120 min. Total- cell extracts were prepared and cellular proteins (20 mg/lane) were sub- jected to 12% SDS-PAGE fractionation and transferred on Immobilon-P membranes. Total tyrosine phosphorylated proteins were detected by Western blotting (WB) with a specific anti-phosphotyrosine monoclonal antibody (PY99 mAb, 1:1000). b) The oFPAEC were treated with or with- out 0.5 mM H2O2 for 20 or 60 min, total tyrosine phosphorylated proteins were immunoprecipitated (IP). The IP samples were analyzed by Western blotting with a specific anti-CAV1 polyclonal antibody (CAV1 pAb, 1: 40 000).

Article Snippet: Materials Anti-CAV1, anti-mitogen-activated protein kinase (MAPK) 8/9 (also termed Jun-NH2-terminal kinase JNK1/2), anti-MAPK11 (also termed p38mapk), and anti-c-src tyrosine kinase (CSK) rabbit polyclonal antibodies (pAb) and anti-phosphotyrosine (PY99) monoclonal antibody (mAb) were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).

Techniques: Phospho-proteomics, SDS Page, Fractionation, Western Blot, Immunoprecipitation

FIG. 10. Tyr14 phosphorylation of caveolin 1 (CAV1) by H2O2 is medi- ated by a CSK-dependent pathway in fetoplacental artery endothelial cells (oFPAEC). a) Serum-starved oFPAEC were pretreated with or without in- creasing concentrations of a specific CSK inhibitor PP2 for 60 min, fol- lowed by treatment with or without 0.2 mM H2O2 for 20 min. Total cell extracts were prepared and equal amounts of proteins (.200 mg/sample) were used for immunoprecipitation (IP) with a specific anti-CSK poly- clonal antibody (5 mg/sample). Tyrosine phosphorylated CSK in the im- munoprecipitates was detected by immunnoblotting (IB) with a specific anti-phosphotyrosine monoclonal antibody (PY99 mAb, 1:1000, upper panel). The membranes were stripped and reprobed with anti-CSK anti- body (1:500) to monitor sample loading (lower panel). b) Total cellular proteins (20mg/lane) from the same experiment as above were analyzed for CAV1 Tyr14 phosphorylation as described in Figure 2. Representative blots of phospho-CSK, Tyr14 phosphorylated CAV1, and total CSK and CAV1 of atypical experiments are shown. Data of mean 6 SEM (n 5 4) of phospho-CSK and Tyr14 phosphorylated CAV1 are summarized in the lower graphs. Means with different letters differ significantly (P , 0.05).

Journal: Biology of reproduction

Article Title: Tyrosine phosphorylation of caveolin 1 by oxidative stress is reversible and dependent on the c-src tyrosine kinase but not mitogen-activated protein kinase pathways in placental artery endothelial cells.

doi: 10.1095/biolreprod.105.040881

Figure Lengend Snippet: FIG. 10. Tyr14 phosphorylation of caveolin 1 (CAV1) by H2O2 is medi- ated by a CSK-dependent pathway in fetoplacental artery endothelial cells (oFPAEC). a) Serum-starved oFPAEC were pretreated with or without in- creasing concentrations of a specific CSK inhibitor PP2 for 60 min, fol- lowed by treatment with or without 0.2 mM H2O2 for 20 min. Total cell extracts were prepared and equal amounts of proteins (.200 mg/sample) were used for immunoprecipitation (IP) with a specific anti-CSK poly- clonal antibody (5 mg/sample). Tyrosine phosphorylated CSK in the im- munoprecipitates was detected by immunnoblotting (IB) with a specific anti-phosphotyrosine monoclonal antibody (PY99 mAb, 1:1000, upper panel). The membranes were stripped and reprobed with anti-CSK anti- body (1:500) to monitor sample loading (lower panel). b) Total cellular proteins (20mg/lane) from the same experiment as above were analyzed for CAV1 Tyr14 phosphorylation as described in Figure 2. Representative blots of phospho-CSK, Tyr14 phosphorylated CAV1, and total CSK and CAV1 of atypical experiments are shown. Data of mean 6 SEM (n 5 4) of phospho-CSK and Tyr14 phosphorylated CAV1 are summarized in the lower graphs. Means with different letters differ significantly (P , 0.05).

Article Snippet: Materials Anti-CAV1, anti-mitogen-activated protein kinase (MAPK) 8/9 (also termed Jun-NH2-terminal kinase JNK1/2), anti-MAPK11 (also termed p38mapk), and anti-c-src tyrosine kinase (CSK) rabbit polyclonal antibodies (pAb) and anti-phosphotyrosine (PY99) monoclonal antibody (mAb) were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).

Techniques: Phospho-proteomics, Immunoprecipitation